Predictive and prognostic biomarkers in breast cancer

Following a breast cancer diagnosis, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy, the most valid of these tests include Oncotype DX and MammaPrint. In the identification of new predictive and prognostic markers, research efforts are focusing on the clinical utility of circulating and tumor DNA as well as the predictive significance of tumor-infiltrating lymphocytes (TILs).   In this exclusive podcast, VJOncology spoke with Judy Garber, MD, MPH, of the Dana-Farber Cancer Institute, Boston, MA, Martine Piccart, MD, PhD, of the Université Libre de Bruxelles, Brussels, Belgium, and Sherene Loi, MBBS, PhD, FRACP, FAHMS from the Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, who outline the role of genetic testing in patients with breast cancer, genomic predictors of response and how a greater understanding of genomics can inform treatment approaches. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).